On Tuesday, Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s shares declined -0.48% to $231.73.
Valeant Pharmaceuticals Intl Inc (VRX) and Progenics Pharmaceuticals, Inc. (PGNX) recently declared that the European Commission has approved RELISTOR(R) (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. The decision effective May 27, 2015 is applicable to all 28 European Union member states plus Iceland and Norway and comprises an additional one year of marketing protection. The European Commission decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) which cited that RELISTOR offers a major contribution to patient care in comparison to existing therapies.
ELISTOR was first approved in Europe in 2008 for the treatment of OIC in advanced illness patients, and is presently approved in more than 50 countries counting the United States.
Valeant Pharmaceuticals International, Inc. develops manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
AstraZeneca plc (ADR) (NYSE:AZN)’s shares dropped -1.27% to $65.38.
AstraZeneca plc (ADR) (AZN) is on the road in support of cholesterol education. Earlier this year, the company launched the “Make Your Move Across America” campaign, an educational initiative offering free lipid screenings and cholesterol education to consumers across the country. The campaign began its journey in Philadelphia, traveled on to Atlanta and Louisville and will now continue on to over 15 community events that span across the country through October 2015. The campaign will visit various cities, counting Washington, D.C, Dallas and Houston, TX, Los Angeles, CA and many more.
High cholesterol is a risk factor for developing heart disease. 71 million American adults (34%) have high LDL-C (bad cholesterol). Of this group, only one out of three adults has their LDL-C level under control. Since high cholesterol has no signs or symptoms, adults must be diagnosed through a lipid profile blood test. Lifestyle modifications, counting a healthy diet and exercise may lower high LDL cholesterol levels. In some cases, when lifestyle changes do not lower cholesterol levels enough, a doctor may recommend a statin, such as CRESTOR® (rosuvastatin calcium). CRESTOR is prescribed together with diet in adults to lower high LDL (“bad”) cholesterol.
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its principal products comprise Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders.
At the end of Tuesday’s trade, Travelers Companies Inc (NYSE:TRV)‘s shares surged 0.04% to $97.80.
Travelers Companies Inc (TRV) will review its second quarter 2015 results at 9 a.m. ET on Tuesday, July 21, following the release of results earlier that morning.
The Travelers Companies, Inc., through its auxiliaries, provides a range of commercial and personal property, and casualty insurance products and services to businesses, government units, associations, and individuals in the Unites states and internationally. It operates in three segments: Business and International Insurance; Bond & Specialty Insurance; and Personal Insurance.
Nuance Communications Inc. (NASDAQ:NUAN), ended its Tuesday’s trading session with 0.03% gain, and closed at $17.46.
Nuance Communications Inc. (NUAN) provider of speech and imaging solutions, recently declared it was named the market leader among global device and print administration independent software vendors by IDC, a leading IT market research and advisory firm. IDC’s report, “Worldwide and U.S. ISV Device and Print Administration Market Shares, 2014: Large Players Remain Strong, Doc # 256347,” was issued last week.
Nuance print administration software enables organizations to control, manage and monitor their entire print environment to reduce costs, bolster security and improve ease-of-use. Nuance works with businesses and managed print services providers to develop comprehensive print administration solutions strategies. Nuance solutions focus on four key areas: security and authentication, hardware fleet optimization, consumables cost reduction and network infrastructure.
Nuance Document Imaging provides software solutions and expertise for professionals and organizations to gain optimal control of their document and information processes. Its expansive portfolio enables strict compliance with information security policies and regulations while enabling organizations to streamline and eliminate gaps across the full spectrum of workflows spanning the lifecycle of their documents from origin to archiving. For users, Nuance’s Imaging solutions deliver an experience that is comprising, familiar and intuitive for more efficient, natural, and intelligent interactions with technologies used to create, capture, and process documents.
Nuance Communications, Inc. provides voice and language solutions for businesses and consumers worldwide. It offers hosted and on-premise solutions and services that provide platforms to generate and distribute clinical documentation through the use of dictation and transcription features; clinical documentation improvement programs; and speech recognition solutions for radiology, cardiology, pathology, and related specialties enabling healthcare providers to dictate, edit, and sign reports without manual transcription.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
